Halozyme Therapeutics Stock Today
| HALO Stock | USD 57.99 0.51 0.87% |
PerformanceSolid
| Odds Of DistressLow
|
Halozyme Therapeutics is selling at 57.99 as of the 26th of February 2025; that is 0.87 percent decrease since the beginning of the trading day. The stock's open price was 58.5. Halozyme Therapeutics has less than a 9 % chance of experiencing financial distress in the next few years and had a solid performance during the last 90 days. Note, on October 4, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Halozyme Therapeutics's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of March 2004 | Category Healthcare | Classification Health Care |
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California. Halozyme Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 123.15 M outstanding shares of which 9.06 M shares are currently shorted by private and institutional investors with about 6.59 trading days to cover. More on Halozyme Therapeutics
Moving together with Halozyme Stock
Moving against Halozyme Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Halozyme Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | MRCP B | ||||
| Thematic Idea | Cancer Fighters (View all Themes) | ||||
| Old Names | [HaloSource Corporation, Halo Labs Inc] | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, ARCA Biotechnology, Jakarta Stock Exchange, SP Midcap 400, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsHalozyme Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Halozyme Therapeutics' financial leverage. It provides some insight into what part of Halozyme Therapeutics' total assets is financed by creditors.
| |||||
Halozyme Therapeutics (HALO) is traded on NASDAQ Exchange in USA. It is located in 12390 El Camino Real, San Diego, CA, United States, 92130 and employs 350 people. Halozyme Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.14 B. Halozyme Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 123.15 M outstanding shares of which 9.06 M shares are currently shorted by private and institutional investors with about 6.59 trading days to cover.
Halozyme Therapeutics currently holds about 209.36 M in cash with 479.06 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.52.
Check Halozyme Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Halozyme Therapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Halozyme Therapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Halozyme Therapeutics. Please pay attention to any change in the institutional holdings of Halozyme Therapeutics as this could imply that something significant has changed or is about to change at the company. On October 4, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Halozyme Therapeutics's common stock.
Check Halozyme Ownership Details
Halozyme Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.9 M | |
| Goldman Sachs Group Inc | 2024-12-31 | 1.9 M | |
| Northern Trust Corp | 2024-12-31 | 1.8 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 1.8 M | |
| Gw&k Investment Management, Llc | 2024-12-31 | 1.7 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.6 M | |
| Nuveen Asset Management, Llc | 2024-09-30 | 1.5 M | |
| Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 1.5 M | |
| Artisan Partners Limited Partnership | 2024-12-31 | 1.4 M | |
| Blackrock Inc | 2024-12-31 | 17.6 M | |
| Vanguard Group Inc | 2024-12-31 | 13.3 M |
Halozyme Therapeutics Historical Income Statement
Halozyme Stock Against Markets
Halozyme Therapeutics Corporate Management
| Mark Esq | Senior Officer | Profile | |
| Kristin Schwartzbauer | Head Quality | Profile | |
| Gary Grote | Chief Officer | Profile | |
| Nicole LaBrosse | CFO Director | Profile | |
| MD MBA | Chief Officer | Profile | |
| Amy Fox | Senior Resources | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.623 | Earnings Share 3.43 | Revenue Per Share | Quarterly Revenue Growth 0.295 | Return On Assets |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.